文献速递妇科产科

美国FDA泌尿妇科网片医疗器械报告的时间趋势分析

Temporal Trends of Urogynecologic Mesh Reports to the U.S. Food and Drug Administration.
PubMed 文献 · Obstet Gynecol · 2020-01-01

该研究利用Reed Tech Navigator工具提取FDA制造商与用户设施设备体验数据库中2000年8月至2019年1月的泌尿妇科合成网片医疗器械报告,比较报告趋势与FDA哨点通知及患者死亡报告。共纳入43,970份报告,97.8%发生于2011年FDA通告之后,峰值在2013年;645份(1.5%)报告死亡,仅4份(0.6%)可直接归因于初次手术。结论认为报告数据常不完整,多数死亡缺乏足够信息判断因果关系,需高质量注册登记。

要点

  • 2000年8月至2019年1月共43,970份泌尿妇科网片医疗器械报告,97.8%在2011年FDA通告后。
  • 64.6%报告涉及压力性尿失禁产品,27.0%涉及经阴道盆腔器官脱垂产品,8.4%涉及经腹部脱垂产品。
  • 645份(1.5%)报告死亡,其中49.3%未明确死因,仅0.6%可直接归因于初次手术。

核心结论

  • 自2011年以来泌尿妇科网片每年产生数千份医疗器械报告,但提交数据常不完整。
  • 报告死亡中少数可直接归因于网片产品,多数缺乏足够信息得出因果结论。
  • 需要高质量注册登记以更好理解泌尿妇科网片产品的患者影响。

研究设计与样本

  • 利用Reed Tech Navigator在线工具提取并分析FDA制造商与用户设施设备体验数据库中的医疗器械报告。
  • 使用FDA产品代码检索2000年8月至2019年1月间压力性尿失禁和盆腔器官脱垂合成网片的报告。
  • 对患者事件中列出「死亡」的报告进行进一步查询。

主要发现

  • 2000年8月至2019年1月共43,970份泌尿妇科网片医疗器械报告,其中43,018份(97.8%)发生于2011年FDA通告之后。
  • 报告构成:压力性尿失禁产品28,422份(64.6%),经阴道盆腔器官脱垂产品11,876份(27.0%),经腹部盆腔器官脱垂产品3,672份(8.4%)。
  • 报告峰值出现在2013年,与首批重大原告判决和阴道网片集体诉讼和解相对应。
  • 645份(1.5%)报告死亡,其中318份(49.3%)未明确死因,仅4份(0.6%)可直接归因于初次手术。

临床怎么用

  • 临床医生应知晓泌尿妇科网片相关医疗器械报告数量大但数据常不完整,解读时需谨慎。
  • 报告死亡多数缺乏足够信息判断因果,不应据此直接推断网片与死亡的因果关系。
  • 支持建立高质量注册登记以系统评估网片产品的患者结局。

局限性

  • 医疗器械报告数据提交常不完整,多数死亡报告缺乏足够信息得出因果结论。
  • 研究为数据库报告分析,可能存在报告偏倚,无法确定真实发生率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare temporal trends of urogynecologic mesh medical device reports with sentinel U.S. Food and Drug Administration (FDA) notices and to examine all linked reports of patient death. METHODS: The Reed Tech Navigator is an online tool used to extract and analyze data in the Manufacturer and User Facility Device Experience database. We used FDA product codes to search for reports of synthetic mesh for stress urinary incontinence (SUI) and pelvic organ prolapse (POP). Reports with "death" listed as a patient event were queried further. RESULTS: There were 43,970 medical device reports involving urogynecologic mesh reported to the FDA between August 2000 and January 2019, with most occurring after the 2011 FDA communication (n=43,018, 97.8%). Of these medical device reports, 64.6% (n=28,422) were for SUI products, 27.0% (n=11,876) were for transvaginal POP products, and 8.4% (n=3,672) were for transabdominal POP products. Peak reporting occurred in 2013, which corresponded with the first major plaintiff verdicts and class action vaginal mesh settlement. There were 645 (1.5%) medical device reports of death, with 49.3% (n=318) having no cause of death identified. Only four (0.6%) could be directly attributed to the initial surgery. CONCLUSION: Since 2011, urogynecologic mesh has been the focus of thousands of medical device reports annually, although the data submitted are often incomplete. Few reported deaths are directly attributable to mesh products, and the majority lack sufficient information to draw causal conclusions. A high-quality registry is necessary to improve our understanding of the patient effect from urogynecologic mesh products.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sassani JC, Artsen AM, Moalli PA, et al. Temporal Trends of Urogynecologic Mesh Reports to the U.S. Food and Drug Administration. Obstet Gynecol. 2020. PMID: 32282600. doi:10.1097/AOG.0000000000003805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。